Brookstone Capital Management Sells 6,299 Shares of AbbVie Inc. $ABBV

Brookstone Capital Management lessened its holdings in AbbVie Inc. (NYSE:ABBV) by 6.4% during the fourth quarter, Holdings Channel.com reports. The firm owned 91,414 shares of the company’s stock after selling 6,299 shares during the quarter. Brookstone Capital Management’s holdings in AbbVie were worth $20,887,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in ABBV. Evolution Wealth Management Inc. purchased a new stake in shares of AbbVie in the 2nd quarter worth approximately $26,000. Chelsea Counsel Co. bought a new position in AbbVie during the 3rd quarter valued at approximately $26,000. Westend Capital Management LLC purchased a new position in AbbVie during the fourth quarter valued at $29,000. Texas Capital Bancshares Inc TX purchased a new position in AbbVie during the third quarter valued at $31,000. Finally, Caitlin John LLC bought a new stake in AbbVie in the third quarter worth $33,000. Institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ABBV. Citigroup reduced their price target on AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a report on Tuesday, January 27th. Barclays assumed coverage on shares of AbbVie in a research note on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price target on the stock. Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 28th. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and raised their price objective for the company from $225.00 to $265.00 in a research note on Wednesday, December 10th. Finally, William Blair reiterated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $253.15.

Insider Activity at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.08% of the stock is owned by insiders.

AbbVie Price Performance

ABBV stock opened at $213.12 on Tuesday. The stock has a market capitalization of $376.83 billion, a P/E ratio of 90.30, a P/E/G ratio of 0.73 and a beta of 0.34. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The business has a fifty day moving average price of $221.93 and a 200-day moving average price of $224.66.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same period last year, the firm posted $2.16 earnings per share. AbbVie’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. AbbVie’s payout ratio is currently 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.